| 1 |
35261903 | Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review. | 2022 Jan |
1 |
| 2 |
32052681 | Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage. | 2021 |
1 |
| 3 |
31608707 | The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. | 2020 Jan |
1 |
| 4 |
32207565 | Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. | 2020 Jun |
1 |
| 5 |
29359239 | The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. | 2018 May |
1 |
| 6 |
30069758 | Regorafenib. | 2018 |
2 |
| 7 |
26419617 | Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. | 2016 May |
1 |
| 8 |
26865419 | Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma. | 2016 May |
1 |
| 9 |
27341596 | Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors. | 2016 May-Jun |
1 |
| 10 |
26327919 | Management of regorafenib-related toxicities: a review. | 2015 Sep |
2 |
| 11 |
24559322 | Regorafenib in metastatic colorectal cancer. | 2014 Mar |
1 |
| 12 |
24756792 | Regorafenib. | 2014 |
2 |
| 13 |
23610528 | Critical appraisal of the use of regorafenib in the management of colorectal cancer. | 2013 |
1 |
| 14 |
22421192 | A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. | 2012 May 1 |
1 |
| 15 |
22577890 | Regorafenib for cancer. | 2012 Jun |
2 |